Abstract
Neuroblastoma is most common extracranialtumor in childrens of less than 5 year. Prognosis of high risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte–macrophage colony-stimulating factor (GM-CSF) or interleukin-2 has been recently approved by FDA for the treatment of high risk neuroblastoma. Dinutuximab binds to the glycolipid GD2 present on neuroblastoma cells and on cells of neuroectodermal origin, and enhances cell lysis through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
